William Blair Reaffirms “Buy” Rating for Autolus Therapeutics (NASDAQ:AUTL)

William Blair reiterated their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a research report sent to investors on Thursday, AnalystRatings.com reports.

A number of other analysts have also commented on the stock. ValuEngine raised shares of Autolus Therapeutics from a hold rating to a buy rating in a research note on Thursday, August 1st. Zacks Investment Research raised shares of Autolus Therapeutics from a sell rating to a hold rating in a research note on Thursday, July 11th. Needham & Company LLC began coverage on shares of Autolus Therapeutics in a research note on Monday, September 23rd. They set a buy rating and a $26.00 price objective for the company. Finally, HC Wainwright reaffirmed a buy rating and set a $24.00 price objective on shares of Autolus Therapeutics in a research note on Thursday, September 12th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $33.33.

AUTL stock traded down $0.34 during trading on Thursday, hitting $12.05. 35,700 shares of the company’s stock traded hands, compared to its average volume of 155,734. Autolus Therapeutics has a 52 week low of $9.50 and a 52 week high of $53.24. The company has a quick ratio of 13.12, a current ratio of 13.12 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $573.69 million, a price-to-earnings ratio of -8.49 and a beta of 0.67. The stock has a fifty day moving average price of $12.51 and a two-hundred day moving average price of $15.66.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.61) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.26. The firm had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $2.00 million. As a group, equities research analysts expect that Autolus Therapeutics will post -3.14 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of AUTL. Exane Derivatives acquired a new position in shares of Autolus Therapeutics in the 2nd quarter valued at about $50,000. CWM LLC increased its holdings in shares of Autolus Therapeutics by 29.3% in the 2nd quarter. CWM LLC now owns 45,384 shares of the company’s stock valued at $731,000 after purchasing an additional 10,274 shares during the period. TD Asset Management Inc. increased its holdings in shares of Autolus Therapeutics by 101.2% in the 2nd quarter. TD Asset Management Inc. now owns 21,229 shares of the company’s stock valued at $342,000 after purchasing an additional 10,680 shares during the period. Artal Group S.A. increased its holdings in shares of Autolus Therapeutics by 11.1% in the 2nd quarter. Artal Group S.A. now owns 500,000 shares of the company’s stock valued at $8,050,000 after purchasing an additional 50,000 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of Autolus Therapeutics in the 2nd quarter valued at about $1,451,000. 51.53% of the stock is owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.

Featured Story: What is the significance of a dead cat bounce?

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit